Abstract
INI-0602, a novel gap junction hemichannel inhibitor, was administered to hemi-Parkinsonism mice generated by striatal 6-hydroxydopamine injection. INI-0602 prevented the toxic activation of microglia, such as the increased number of the activated form, enlargement of cell bodies and induction of proinflammatory cytokines, such as IL-1β and TNFα, in the ipsilateral striatum. On the other hand, INI-0602 induced the expression of neurotrophic factors, such as brain-derived neurotrophic factor and NT-4/5, in the 6-hydroxydopamine-treated striatum. INI-0602 treatment blocked not only dopaminergic loss in both the striatum and substantia nigra, but also apomorphine-induced rotational behavior.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akiyama H, McGeer PL (1989) Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res 489:247–253. doi:10.1016/0006-8993(89)90857-3
Barger SW, Basile AS (2001) Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. J Neurochem 76:846–854. doi:10.1046/j.1471-4159.2001.00075.x
Block ML, Hong JS (2007) Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35(Pt5):1127–1132. doi:10.1042/BST0351127
Calabresi P, Galletti F, Saggese E, Ghiglieri V, Picconi B (2007) Neuronal networks and synaptic plasticity in Parkinson’s disease: beyond motor deficits. Parkinsonism Relat Disord 13(Suppl. 3):S259–S262. doi:10.1016/S1353-8020(08)70013-0
Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, Parks JP, Parker WD, Bennett JP (1998) Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson’s disease. Biochim Biophys Acta 1362:77–86. doi:10.1016/S0925-4439(97)00070-7
Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK (1992) Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 149:2736–2741
Chase TN, Oh JD (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23(Suppl. 1):S86–S91. doi:10.1016/S1471-1931(00)00018-5
Floden AM, Li S, Combs CK (2005) Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 25:2566–2575. doi:10.1523/JNEUROSCI.4998-04.2005
Hunot S, Boissière F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience 72:355–363. doi:10.1016/0306-4522(95)00578-1
Johnson KA, Conn PJ, Niswender CM (2009) Glutamate receptors as therapeutic targets for Parkinson’s disease. CNS Neurol Disord Drug Targets 8:475–491. doi:10.2174/187152709789824606
Juszczak GR, Swiergiel AH (2009) Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry 33:181–198. doi:10.1016/j.pnpbp.2008.12.014
Kreutzberg GM (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosciences 19:312–318. doi:10.1016/0166-2236(96)10049-7
Laird DW (2010) The gap junction proteome and its relationship to disease. Trends Cell Biol 20:92–101. doi:10.1016/j.tcb.2009.11.001
Nagatsu T, Sawada M (2006) Cellular and molecular mechanisms of Parkinson’s disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol 26:781–802. doi:10.1007/s10571-006-9061-9
Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Cytokines in Parkinson’s disease. J Neural Transm Suppl 58:143–151. doi:10.1007/978-3-7091-6284-2_12
Nelson PT, Soma LA, Lavi E (2002) Microglia in disease of the central nervous system. Ann Med 34:491–500. doi:10.1080/078538902321117698
Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27:119–145. doi:10.1146/annurev.immunol.021908.132528
Sawada M, Suzumura A, Marunouchi T (1995) Cytokine network in the central nervous system and its roles in growth and differentiation of glial and neuronal cells. Int J Dev Neurosci 13:253–264. doi:10.1016/0736-5748(94)00076-F
Shen W, Flajolet M, Greengard P, Surmeier DJ (2008) Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321:848–851. doi:10.1126/science.1160575
Suzuki H, Imai F, Kanno T, Sawada M (2001) Preservation of neurotrophin expression in microglia that migrate into the gerbil’s brain across the blood–brain barrier. Neurosci Lett 312:95–98. doi:10.1016/S0304-3940(01)02198-X
Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, Kuno R, Suzumura A (2005) Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 280:10444–10454. doi:10.1074/jbc.M413863200
Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A (2006) Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 28:21362–21368. doi:10.1074/jbc.M600504200
Takeuchi H, Jin S, Suzuki H, Doi Y, Liang J, Kawanokuchi J, Mizuno T, Sawada M, Suzumura A (2008) Blockade of microglial glutamate release protects against ischemic brain injury. Exp Neurol 214:144–146. doi:10.1016/j.expneurol.2008.08.001
Takeuchi H, Mizoguchi H, Doi Y, Jin S, Noda M, Liang J, Li H, Zhou Y, Mori R, Yasuoka S, Li E, Parajuli B, Kawanokuchi J, Sonobe Y, Sato J, Yamanaka K, Sobue G, Mizuno T, Suzumura A (2011) Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer’s disease. PLoS One 6:e21108. doi:10.1371/journal.pone.0021108
Vilhardt F, Plastre O, Sawada M, Suzuki K, Wiznerowicz M, Kiyokawa E, Trono D, Krause KH (2002) The HIV-1 Nef protein and phagocyte NADPH oxidase activation. J Biol Chem 277:42136–42143. doi:10.1074/jbc.M200862200
Zou JY, Crews FT (2005) TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 1034:11–24. doi:10.1016/j.brainres.2004.11.014
Acknowledgments
The authors thank Dr. A. Suzumura for providing INI-0602.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Suzuki, H., Ono, K. & Sawada, M. Protective effect of INI-0602, a gap junction inhibitor, on dopaminergic neurodegeneration of mice with unilateral 6-hydroxydopamine injection. J Neural Transm 121, 1349–1355 (2014). https://doi.org/10.1007/s00702-014-1209-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-014-1209-z